Mean change in total T1‐hypointense lesion load · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Outcomes at 24 months · patients with relapsing‐remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg showed no clear difference in withdrawals due to adverse events compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from MRI gadolinium‐enhancing lesions compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with placebo (moderate certainty).
1 finding from 1 review
Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg may leads to higher participants free from disability worsening compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether fingolimod 0.5 mg changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with placebo (moderate certainty).
1 finding from 1 review
Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg may leads to higher participants free from MRI gadolinium‐enhancing lesions compared with placebo (low certainty).
1 finding from 1 review
Outcomes at 12 months · patients with relapsing‐remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg showed no clear difference in participants free from disability worsening compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Relapse · relapsing multiple sclerosis
Teriflunomide may leads to lower proportion of participants with at least 1 relapse at 1 year compared with placebo (low certainty).
2 findings from 1 review
Number of participants experiencing disability progression · relapsing multiple sclerosis
It is very uncertain whether teriflunomide changes the proportion of participants with disability progression at 1 year compared with placebo (very low certainty).
2 findings from 1 review
Diarrhoea · relapsing multiple sclerosis
Teriflunomide probably leads to higher the proportion of participants with diarrhoea at 2 years compared with placebo (moderate certainty).
1 finding from 1 review
The proportion of participants with hair thinning at 2 years · relapsing multiple sclerosis
Teriflunomide probably leads to higher the proportion of participants with hair thinning at 2 years compared with placebo (moderate certainty).
1 finding from 1 review
The proportion of participants with elevated ALT levels at 2 years · relapsing multiple sclerosis
Teriflunomide probably leads to higher the proportion of participants with elevated ALT levels at 2 years compared with placebo (moderate certainty).
1 finding from 1 review
Overall survival · All patients with a diagnosis of multiple myeloma
Bortezomib leads to lower overall Survival compared with no bortezomib (high certainty).
1 finding from 1 review
Health‐related quality of life · All patients with a diagnosis of multiple myeloma
1 finding from 1 review